RSCM
ENTA icon

Rock Springs Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Rock Springs Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-92,500
Closed -$7.91M – 139
2018
Q3 		$7.91M Buy
+92,500
New +$9.27M 0.29% 96

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Rock Springs Capital Management's ENTA Position: Q4 2018 in Review

Rock Springs Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2018, closing a stake of 92,500 shares — an estimated $7.91M sold.

Rock Springs Capital Management first reported a position in ENTA in Q3 2018 and held it in 1 quarter. The position peaked at $7.91M in Q3 2018. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

  • Rock Springs Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Rock Springs Capital Management sold 92,500 Enanta Pharmaceuticals shares in Q4 2018, an estimated $7.91M.
  • Rock Springs Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Rock Springs Capital Management's Enanta Pharmaceuticals position peaked at $7.91M in Q3 2018.
  • 183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on Rock Springs Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.